to join the discussion
HCI punching through 166 today on decent momentum. At these levels the dividend yield is starting to look respectable for a financials play, though you'd want to see earnings growth sustaining before getting too excited.
Topped up HCI at 16387 this morning after that solid earnings beat last week, reckon the financials rally still has legs despite the rate cut cycle slowing down.
HCI's flat performance today masks the structural divergence versus Remgro, which benefits from more direct equity exposure to operating businesses rather than HCI's sprawling conglomerate discount. The unbundling thesis remains compelling if management extracts value from Medicl
HCI flat today despite the broader market noise, which frankly tells you nothing about the underlying value creation. The real question is whether Hosken's portfolio companies are generating adequate ROIC on deployed capital, particularly given current economic headwinds and the
HCI trades at roughly 0.6x P/B against Remgro's 0.8x, yet the conglomerate discount seems excessive given embedded value in Inanda and the Mediclinic stake, particularly when comparing unlevered ROIC across the portfolio to peers earning single-digit returns on equity. The flat p
HCI's pullback to R16307 on light volume feels overdone given the structural earnings quality from its Primedia and Fameccanica holdings, though the 16x forward multiple leaves limited margin of safety until we see more momentum in advertising spend. The discount to intrinsic val
HCI taking a 3.72% knock today, but I'm more interested in whether management can sustain that dividend growth trajectory we've seen over the past few years rather than getting caught up in daily volatility. The conglomerate's payout ratio has been reasonable, so if they maintain
Market's selling HCI off 1.37% today but this feels like panic money missing the forest for the trees. The financial services conglomerate's diversified earnings streams across insurance, investment management, and property have proven remarkably resilient through credit cycles,
HCI's valuation at R17,171 remains compelling for patient capital when you consider the embedded value in its diversified portfolio of financial services, logistics, and media assets, many of which trade at significant discounts to intrinsic value individually. The conglomerate s
Trimmed my HCI position at R17,161 following the recent capital deployment announcements, given the embedded value accretion narrative has already priced in much of the upside from their unbundling pipeline and I'm rotating capital into more immediate special situations with clea
HCI down 1.79% today but the discount to net asset value remains compelling versus Remgro, which trades closer to fair value despite similar portfolio quality and diversification risk. The unlisted asset drag on NAV is eish, yet the listed equity holdings like Mediclinic and Hosk
HCI's trading at R17212 today reflects patient capital positioning ahead of potential unbundling catalysts, though the holding company discount versus NAV remains wider than peers like Remgro despite comparable operational ROIC across their portfolios. The 0.95% move feels measur
HCI's creep upward at R17,126 masks the structural headwinds in its diversified portfolio. The holding company discount persists because investors struggle to value circular cross-holdings between Hosken entities and NewsCorp interests, while earnings visibility on the insurance
HCI holding steady at R17204 despite the rand volatility we're seeing this week. From a supply chain perspective, their diversified portfolio across logistics, food distribution, and industrial services means they're capturing margin expansion as input costs stabilise, particular
HCI down 2% today, which honestly feels like noise given the conglomerate's diversified earnings streams across logistics, healthcare, and financial services. The market's been jittery on financials lately, but I'd want to see where the P/E sits relative to historical averages be
HCI's conglomerate structure trades at a substantial discount to sum-of-parts valuation, particularly when benchmarked against Remgro's more celebrated portfolio management and the opaque holding company discounts plaguing most JSE diversified plays. The group's embedded value in
Hosken Cons Inv LTD (HCI) catching a bid today, +1.8% at R17148.00. Added.
Trimmed my HCI position on the back of rand strength and declining embedded value per share, given the fund's significant rand-denominated liabilities and the fact that offshore equity exposure alone doesn't justify a 25% premium to NAV when global rates remain elevated.
HCI's long-term trajectory hinges on management's ability to navigate its sprawling portfolio through this credit cycle while maintaining disciplined capital allocation. The counter's valuation at current levels offers meaningful upside for patient investors who can tolerate the
HCI's exposure to the energy transition through its various holdings puts it in an interesting position as SA pivots away from coal, though the real question is whether management can unlock value faster than the market prices in this structural shift. At current levels with the